Based on 7 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is €56.61 with a high forecast of €72.36 and a low forecast of €49.21. The average price target represents a 65.52% change from the last price of €34.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","46":"€46","73":"€73","32.5":"€32.5","59.5":"€59.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72.364875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€72.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.60862955,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€56.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.208115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€49.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,32.5,46,59.5,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55,56.33575961538462,57.67151923076923,59.007278846153845,60.34303846153846,61.67879807692307,63.01455769230769,64.35031730769231,65.68607692307693,67.02183653846154,68.35759615384615,69.69335576923076,71.02911538461538,{"y":72.364875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55,55.12374073461538,55.24748146923077,55.37122220384615,55.49496293846154,55.61870367307692,55.74244440769231,55.86618514230769,55.98992587692308,56.11366661153846,56.23740734615385,56.36114808076923,56.48488881538462,{"y":56.60862955,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55,54.554470384615385,54.10894076923077,53.663411153846155,53.21788153846154,52.772351923076926,52.32682230769231,51.88129269230769,51.435763076923074,50.99023346153846,50.544703846153844,50.09917423076923,49.653644615384614,{"y":49.208115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.6,"date":1703203200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.8,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.6,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.4,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€72.36

Average Price Target€56.61

Lowest Price Target€49.21

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Reiterated

12/20/24

Reiterated

12/10/24

Assigned

12/09/24

xxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

12/09/24

Reiterated

12/09/24

Assigned

10/23/24

Initiated

10/10/24

xxxxxxxxxxxxx

Tessa Romero

J.P. Morgan

€44.38

Hold

29.78%

Upside

Initiated

06/13/24

Agios Pharmaceuticals reinstated with a Neutral at JPMorganAgios Pharmaceuticals reinstated with a Neutral at JPMorgan

Salveen Richter

Goldman Sachs

€31.84→€51.14

Hold

49.53%

Upside

Reiterated

06/04/24

Agios Pharma (AGIO) PT Raised to $53 at Goldman SachsGoldman Sachs analyst Salveen Richter raised the price target on Agios Pharma (NASDAQ: AGIO) to $53.00 (from $33.00) while maintaining a Neutral rating.

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

05/28/24

Agios investors paying nothing for Pyrukynd, says Cantor FitzgeraldAgios investors paying nothing for Pyrukynd, says Cantor Fitzgerald

Best Analysts Covering Agios Pharma

Which Analyst Should I Follow If I Want to Buy DE:8AP and Sell After:

1 Month

xxx

Success Rate

8/9 ratings generated profit

Average Return

+4.64%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 88.89% of your transactions generating a profit, with an average return of +4.64% per trade.

3 Months

xxx

Success Rate

6/9 ratings generated profit

Average Return

+3.94%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.94% per trade.

1 Year

Gregory RenzaRBC Capital

Success Rate

15/23 ratings generated profit

Average Return

+21.23%

assigned a buy rating 13 days ago

Copying Gregory Renza's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +21.23% per trade.

2 Years

xxx

Success Rate

18/23 ratings generated profit

Average Return

+34.75%

assigned a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.26% of your transactions generating a profit, with an average return of +34.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8AP Analyst Recommendation Trends

Rating

Aug 24

Sep 24

Oct 24

Nov 24

Dec 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 8AP has received 14 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 8AP average Analyst price target in the past 3 months is €56.61.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

8AP Financial Forecast

8AP Earnings Forecast

Next quarter’s earnings estimate for 8AP is -€1.61 with a range of -€1.77 to -€1.47. The previous quarter’s EPS was €15.44. 8AP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 53.85% of the time in the same period. In the last calendar year 8AP has Underperformed its overall industry.

8AP Sales Forecast

Next quarter’s sales forecast for 8AP is €8.89M with a range of €8.05M to €10.42M. The previous quarter’s sales results were €8.54M. 8AP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.69% of the time in the same period. In the last calendar year 8AP has Underperformed its overall industry.

8AP Stock Forecast FAQ

What is DE:8AP’s average 12-month price target, according to analysts?

Based on analyst ratings, Agios Pharma’s 12-month average price target is €56.61.

What is DE:8AP’s upside potential, based on the analysts’ average price target?

Agios Pharma has 65.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Agios Pharma a Buy, Sell or Hold?

Agios Pharma has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Agios Pharma’s share price target?

The average share price target for Agios Pharma is €56.61. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €72.36 ,and the lowest forecast is €49.21. The average share price target represents 65.52% Increase from the current price of €34.2.

What do analysts say about Agios Pharma?

Agios Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Agios Pharma?

To buy shares of DE:8AP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Agios Pharma (8AP) Stock Forecast & Price Target

8AP Analyst Ratings

8AP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agios Pharma

8AP Analyst Recommendation Trends

8AP Financial Forecast

8AP Earnings Forecast

8AP Sales Forecast

8AP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts